The combination of the toripalimab, a humanized anti–PD-1 monoclonal antibody, in combination with the inhibitor of vascular endothelial growth factor (VEGF) receptor, axitinib for advanced MM showed an ORR of 48.3% and a disease control rate (DCR) of 86.2% [182,190]. Here, VEGFA is linked to Miyoshi myopathy.